<DOC>
	<DOC>NCT01844895</DOC>
	<brief_summary>The purpose of this study is to implement a substudy in approximately 120 rheumatoid arthritis (RA) subjects to compare the steady-state serum trough concentration (Cminss), Cmax and area under the curve (AUC) during the dosing interval (TAU) of subcutaneous (SC) Abatacept injection of 125 mg via the autoinjector and via the BD Hypakâ„¢ Physiolis prefilled syringe.</brief_summary>
	<brief_title>Methotrexate-Inadequate Response Autoinjector Device Sub Study</brief_title>
	<detailed_description>Study Classification: - Safety: show if the drug is safe under conditions of proposed use - Efficacy: measure of an intervention's influence on a disease or health condition - Safety/Efficacy - Pharmacokinetics: the action of a drug in the body over a period of time including the process of absorption, distribution and localization in tissue, biotransformation, and excretion of the compound.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects who have been treated in the long term (LT) with openlabel SC Abatacept for at least 3 months Must continue to meet inclusion criteria specified in main IM101174 Study Protocol Participation in previous device substudy (implemented by Amendment 10) Must continue to meet exclusion criteria specified in main IM101174 Study Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>